Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lemtrada A Game Changer In MS, Genzyme Researchers Say

Mar 22 2013

• By Shirley Haley

Related Content

Pharma Industry Support For Republican And Democratic Conventions Plummets

Aug 27 2012

Genzyme <em>Lemtrada</em>’s Momentum Halts With FDA “Refuse-To File” Letter

Aug 27 2012

Sanofi Sets Sights On Multiple Sclerosis Leadership

Apr 30 2012

Biogen Idec Ramps Up For BG-12, Dubs The MS Drug Tecfidera

Jan 28 2013

Sanofi’s <em>Aubagio</em> And Biogen Idec’s <em>Tecfidera</em> Make It A Good Day For MS Sufferers At EMA

Mar 22 2013

<em>Aubagio</em> Approval Reflects FDA’s Evolving View On Multiple Sclerosis Drugs

Mar 19 2013

Biogen Idec's BG-12 Results Up The Ante In The Oral MS Market

Apr 21 2011

Sanofi/Genzyme MS Drug <em>Lemtrada</em> Scores High Against <em>Rebif</em>

May 01 2012

Genzyme Prices MS Drug Aubagio At Discount To Established Therapies

Sep 13 2012

Related Companies

Sanofi

Sanofi Genzyme

Novartis AG

Roche Holding AG

Bayer AG

Teva Pharmaceutical Industries Ltd.

Additional Topics

Clinical Trials BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window